Fig 1.

Tocilizumab reduces the concentration of circulating serum inflammatory cytokines and clinical laboratory variables. Top panel (A–D): levels of serum interleukin (IL)‐1β, IL‐6, IL‐10 and tumour necrosis factor alpha (TNF‐α) for each patient. Vertical dashed lines represent the timing of tocilizumab administration relative to daily measurements of cytokines. Bottom Panel (E–H): levels for lymphocyte count, C‐reactive protein, ferritin and D‐dimer for each patient. Vertical dashed lines represent the timing of tocilizumab administration relative to daily measurements of clinical laboratory value. *denotes a significant difference from Day 0, P < 0·05.